Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15220550 | 0.86 | TDP1 (0.56) | MAPK1ALOX15HSD17B10L3MBTL1TSHR | |
| SCHEMBL8311312 | 0.85 | MAPK1 (0.55) | MAPK1ALOX15HSD17B10L3MBTL1TSHR | |
| SCHEMBL30198648 | 0.85 | MAPK1 (0.55) | MAPK1ALOX15HSD17B10L3MBTL1TSHR | |
| SCHEMBL1962854 | 0.83 | GPR35 (0.55) | MAPK1ALOX15HSD17B10L3MBTL1TSHR | |
| Hydrochloric Acid SCHEMBL27568534 | 0.83 | MAPK1 (0.53) | MAPK1ALOX15HSD17B10L3MBTL1TSHR | |
| SCHEMBL10907363 | 0.83 | GPR35 (0.55) | MAPK1ALOX15HSD17B10L3MBTL1TSHR | |
| SCHEMBL4964293 | 0.82 | TDP1 (0.52) | MAPK1ALOX15HSD17B10L3MBTL1TSHR | |
| SCHEMBL1399686 | 0.82 | TSHR (0.52) | MAPK1ALOX15HSD17B10L3MBTL1TSHR | |
| SCHEMBL94283 | 0.81 | GPR35 (0.62) | MAPK1ALOX15HSD17B10L3MBTL1TSHR | |
| SCHEMBL2892616 | 0.81 | GPR35 (0.62) | MAPK1ALOX15HSD17B10L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118806618-A | Hair cleansing compositions | 日本乐敦制药株式会社 | 2024-10-22 | — | — | CN | disclosed |
| CN-111201009-B | Hair cleansing compositions | 日本乐敦制药株式会社 | 2024-08-16 | — | — | CN | disclosed |
| CN-107253914-B | The method for preparing 2- Amino-4-nitrophenol using Disperse Blue 2BLN byproduct | 青岛海湾集团有限公司 | 2019-10-25 | — | — | CN | disclosed |
| US-20040235908-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | SCHERING CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | PHARMACOPEIA, INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1355875-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2003-05-22 | — | — | US | disclosed |
| WO-2002076926-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC CHEMOKINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-0093369-B1 | REACTIVE DYES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| EP-0093369-A2 | Reactive dyes | BAYER AG (DE) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235908-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | CCR1, CXCR1, ACKR3 | MAPK1 438/4885ALOX15 349/4885HSD17B10 895/4885 |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | CCR1, ACKR3, CXCR1 | MAPK1 358/4885ALOX15 634/4885HSD17B10 788/4885 |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | CCR1, CXCR1, ACKR3 | MAPK1 438/4885ALOX15 349/4885HSD17B10 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.